4
Changes in Ownership
4D Molecular Therapeutics, Inc. Filed Acc 0001193125-26-361096
See Remarks sold 69,076 shares at an average $15.75 ($1,088,273)
- See Remarks acquired 50,000 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Table I: Non-derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Kirn David See Remarks | 2026-08-19 | Option exercise 10b5-1 | +50,000 | $4.14 | $207,000 | 894,895 | D: show line 1 in the form |
| Kirn David See Remarks | 2026-08-19 | Sale 10b5-1 | −43,149 | $15.36 | $662,622 | 851,746 | D: show line 2 in the form |
| Kirn David See Remarks | 2026-08-19 | Sale 10b5-1 | −25,927 | $16.42 | $425,651 | 825,819 | D: show line 3 in the form |
| Open-market sales · 69,076 sh · avg $15.75 · $1,088,273 | |||||||
Table II: Derivative
| Insider | Date | Transaction | Shares | Price | Value | Exercise | Expires | Underlying | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|
| Kirn David See Remarks | 2026-08-19 | Option exercise · Stock Option (Right to Buy) 10b5-1 | −50,000 | 217,500 | D: show line 4 in the form |
Loading xslF345X06/ownership.xml…